Alzamend Neuro (ALZN) Return on Capital Employed [ROCE] (2021 - 2026)
Alzamend Neuro's Return on Capital Employed [ROCE] was -342.74% in fiscal Q4 2023 (quarter ended Apr 30, 2023), down 242.65 percentage points from -100.09% a year earlier and down 116.41 percentage points from the prior quarter.
Powered by 
Analysis
Alzamend Neuro (ALZN) Return on Capital Employed [ROCE] (2021 - 2026) Analysis & Trends
For FY2023 (ended Apr 30, 2023), Return on Capital Employed [ROCE] at Alzamend Neuro came in at -202.43%, down 39.25 percentage points from FY2022.
- In earlier fiscal years, Return on Capital Employed [ROCE] was -163.18% in FY2022 (+175.14 pp) and -338.32% in FY2021.
- The fiscal Q4 2023 figure marks the lowest quarterly Return on Capital Employed [ROCE] in data going back to fiscal Q1 2022.
- Compared with a year earlier, Return on Capital Employed [ROCE] has declined for four straight quarters, with an average year-over-year change of -125.37 percentage points over the last four quarters.
- Per Business Quant data, ALZN's Return on Capital Employed [ROCE] in the three fiscal quarters before Q4 2023 was -226.34% (Q3 2023), -129.87% (Q2 2023) and -105.79% (Q1 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 35.41% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 17.52% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 21.60% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 4.65% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 9.91% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 17.37% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | -6.15% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 11.32% |
| 10 | Alzamend Neuro | 6.51 Mn | -8.95 Mn | - | -353.59% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | -353.59% |
| Apr 30, 2026 | -511.35% |
| Jan 31, 2026 | -259.64% |
| Oct 31, 2025 | -117.69% |
| Jul 31, 2025 | -139.12% |
| Apr 30, 2025 | -119.77% |
| Jan 31, 2025 | -108.85% |
| Oct 31, 2024 | -279.77% |
| Jul 31, 2023 | -1,003.37% |
| Apr 30, 2023 | -342.74% |
| Jan 31, 2023 | -226.34% |
| Oct 31, 2022 | -129.87% |
| Jul 31, 2022 | -105.79% |
| Apr 30, 2022 | -100.09% |
| Jan 31, 2022 | -74.37% |
| Oct 31, 2021 | -57.99% |
| Jul 31, 2021 | -70.78% |
API Access
Alzamend Neuro Return on Capital Employed [ROCE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=ALZN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-capital-employed-[roce]", "ticker": "ALZN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=ALZN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();